The pharmaceutical sector has changed! Guizhou Sanli, Saili Medical and many other stocks rose to the limit

【Pharmaceutical Network Pharmaceutical Stock Market】On December 2, the pharmaceutical sector changed again, from the perspective of individual stocks, traditional Chinese medicine stocks Guizhou Sanli, Fengyuan Pharmaceutical, etc.
touched the limit of increase, pharmaceutical commercial stocks Saili Medical, Jiashitang, etc.
also walked out of the limit of increase, and many stocks such as Shuyu Civilian, Yixintang, and Kangyuan Pharmaceutical followed suit
.
As of 11:48, Guizhou Sanli rose to the limit, the quotation was 17.
48 yuan, the turnover was 425 million, the turnover rate was 15.
14%, and the price-to-earnings (TTM) was 49.
88
.
According to the analysis, the reasons for the change in the stock include: the company is a traditional Chinese medicine enterprise, with products such as Huo Xiang Zhengqi Capsules, Angong Niuhuang Pills, and Suhe Xiang Pills, and has launched new drug research and registration projects
for 6 classic Chinese medicine series.
In addition, the company also invested in the establishment of Xiaoqi Pharmaceutical Technology (Chengdu) Co.
, Ltd.
in July 21, mainly cooperating with hospitals to carry out Internet hospitals, online diagnosis and treatment, chronic disease management and other businesses
.
As of 11:48, Fengyuan Pharmaceutical rose to the limit, the quotation was 14.
30 yuan, the turnover was 932 million, the turnover rate was 22.
05%, and the price-to-earnings (TTM) was 31.
48
.
Fengyuan Pharmaceutical is also a Chinese medicine stock, whose main business is the research and development, production and sales of biological drugs, chemical drugs and traditional Chinese medicines; Pharmaceutical distribution and pharmacy retail
.
and the production of ophthalmic drugs; According to the 2021 annual report, the company's cinidipine tablet products are used for the treatment
of hypertension.
In addition, Anhui Fengyuan Pharmacy Chain Company, a wholly-owned subsidiary, is mainly engaged in the sales of Chinese and Western medicines, medical devices, health foods, etc.
, through the unique business model
of joint operation of pharmacies and clinics, coexistence of central stores and community convenience stores, and supermarket hypermarkets and specialty pharmacies.
As of 11:48, Celi Medical rose to the limit, quoted 14.
08 yuan, the turnover was 482 million, the turnover rate was 17.
14%, and the price-earnings (TTM) loss
.
The stock has risen 14 times
in the past year.
The main business of Celi Medical is intensive sales, simple sales and independent in vitro diagnostic product development, production and sales, the main products are diagnostic reagents and consumables, in vitro diagnostic instruments and equipment
.
The company is developing smart hospital solutions based on the integration of "SPD+CDSS+DRGs", and has the production capacity of IgM/IgG antibody detection kit (colloidal gold immunochromatography), which has obtained the EU CE certification
.
At the same time, the company has obtained the domestic registration certificate of specific protein analyzer in 2016, and has the production capacity
of specific protein analyzer.
In the field of antihypertensive drugs, in June 2021, its subsidiary Hua Jiyuan reached a strategic cooperation with Jiangsu Yaohai Biotechnology on the joint development project of therapeutic antihypertensive vaccines, further promoting the research and development progress
of antihypertensive vaccines.
As of 11:48, Jiashitang also rose to the limit, with a quotation of 18.
82 yuan, a turnover of 895 million, a turnover rate of 17.
06%, and a price-to-earnings (TTM) of 16.
37
.
Jiashitang is the main platform of Everbright Health Business Sector, and Celi Medical belongs to the pharmaceutical business concept stock, the company adheres to the vision of "healthy and happy companionship of a better life", adheres to the concept of "innovation, science and technology, and beyond", actively grasps market changes, implements reform and innovation, expands innovative business with the support of informatization, and comprehensively enhances the competitiveness of pharmaceutical sales, medical device sales, pharmaceutical retail, pharmaceutical logistics and innovative business
.
.
.
.
.
.
.
Recently, the pharmaceutical business sector and the traditional Chinese medicine sector have performed well
.
The analysis believes that the reasons for the recent changes in the pharmaceutical commercial sector are mainly related to the issuance of the Measures for the Supervision and Administration of Drug Online Sales, which will help China's pharmaceutical circulation industry achieve a new stage of transformation and upgrading under the new regulations, in addition to the high incidence of influenza in winter, the "twenty articles" are also catalytic factors
.
The traditional Chinese medicine sector is also affected
by favorable policies.
Kaiyuan Securities pointed out that the new epidemic prevention policy is expected to bring about a rapid recovery of consumer medical care, which is good for the traditional Chinese medicine sector, which is currently low in valuation and friendly policies, coupled with the recovery of in-hospital and out-of-hospital traffic, performance and prosperity are expected to continue to improve
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.